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In their recent meta-analysis, Vlaanderen et al. 
(2011) claimed to show evidence for associa-
tions between occupational benzene exposure 
and risks of multiple myeloma, acute lympho-
cytic leukemia, and chronic lymphocytic leu-
kemia. However, one of the larger available 
studies, including 5,514 benzene-exposed UK 
workers (Sorahan et al. 2005), was excluded 
from this meta-analysis, apparently because 
the study had an elevated standardized mortal-
ity ratio (SMR) for secondary and unspecified 
cancers. On the basis of national mortality 
rates, we would have expected 7% of all can-
cer deaths in the UK study to have been in 
the unspecified cate  gory (e.g., carcinomatosis, 
mesothelioma with site unspecified); however, 
9% of deaths were unspecified. Given the size 
of the study (2,430 deaths from all causes), 
this difference was statistically significant 
(Sorahan et al. 2005). Is it reasonable to con-
clude that a study with 93% of cancer deaths 
with site of cancer specified is informative but 
one with only 91% specified is not? I do not 
believe that it is. Vlaanderen et al. (2011) are 
of course free to come to a different conclu-
sion, but any conclusion they reach must be 
implemented in an even-handed way. Some 
obvious questions then arise: a) How elevated 
did the SMR for unspecified cancers have 
to be for a study to be excluded from their 
meta-analysis? b) Were all the other studies 
assessed against this criterion? c) How many 
studies did not provide enough information 
for this criterion to be assessed? d) Why was 
this number not supplied by Vlaanderen et al. 
(2011)? 
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We appreciate Sorahan’s interest in our study 
(Vlaanderen et al. 2011). We first evaluated 
the article by Sorahan et al. (2005) for inclu-
sion in our meta-analysis based on its analy-
sis of cancer incidence, which is consistent 
with our stated preference for using incidence 
rather than mortality data when both were 
available (Vlaanderen et al. 2011). Because the 
authors themselves had expressed serious con-
cerns with regard to the under  ascertainment 
of cancer registrations (incidence) (Sorahan 
et al. 2005), we decided not to include these 
data and instead considered their mortality 
analysis, which was included in the same arti-
cle (Sorahan et al. 2005). We then decided to 
exclude their mortality data as well because of 
their “inability to identify the type of cancer 
for a number of cancer deaths” (Vlaanderen 
et al. 2011). A total of 9% of all cancer deaths 
were not identified by type by Sorahan et al. 
(2005), compared to 2–6% from the publica-
tions we considered for inclusion that pro-
vided such data (9 of 40 cohorts reviewed). 
We did not make this decision based on the 
SMR for this category, as Sorahan claimed 
in his letter. Inclusion of the mortality data 
from Sorahan et al. (2005) has a negligible 
impact on our results [Table 1 compared with 
Supplemental Material, Table 1 of our paper 
(http://dx.doi.org/10.1289/ehp.1002318)] 
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Table 1. Pooled risk estimates (and 95% confidence intervals) for AML and five lymphoma subtypes stratified by start of 
follow-up and AML significance level and including data from Sorahan et al. (2005).
Lymphoma subtype/
AML significance 
levela
No. of 
studies 
No. of 
cases
Meta relative 
risk (all studies)
No. of 
studies 
No. of 
cases
Meta risk ratio 
(start follow-up 
before 1970)
No. of 
studies 
No. of 
cases
Meta risk ratio 
(start follow-up 
1970 and later)
AML
A–E (all studies) 22 229 1.69 (1.38–2.08)* 13 131 1.47 (1.12–1.92)* 9 98 2.08 (1.59–2.72)
A–D 22 229 1.69 (1.38–2.08)* 13 131 1.47 (1.12–1.92)* 9 98 2.08 (1.59–2.72)
A–C 17 204 1.87 (1.57–2.22) 9 112 1.72 (1.38–2.15) 8 92 2.11 (1.61–2.77)
A–B 12 144 2.15 (1.76–2.63) 6 76 1.99 (1.51–2.60) 6 68 2.41 (1.77–3.29)
A 10 120 2.38 (1.89–2.99) 5 63 2.13 (1.57–2.89) 5 57 2.88 (1.95–3.99) 
HL
A–E (all studies) 28 149 1.00 (0.84–1.18) 20 126 1.01 (0.84–1.23) 8 23 0.91 (0.59–1.40)
A–D 13 72 0.99 (0.78–1.27) 9 61 1.03 (0.79–1.35) 4 11 0.83 (0.47–1.48)
A–C 10 42 0.84 (0.61–1.16) 6 31 0.84 (0.57–1.24) 4 11 0.83 (0.47–1.48)
A–B 6 10 0.57 (0.30–1.10) 3 9 0.65 (0.31–1.38) 3 1b 0.40 (0.11–1.44)
A 5 10 0.61 (0.31–2.19) 3 9 0.65 (0.31–1.38)   2 1c 0.46 (0.10–2.09)
NHLd
A–E (all studies) 34 662 1.00 (0.89–1.12)* 23 467 0.93 (0.82–1.05) 11 195 1.21 (0.94–1.55)*
A–D 16 398 0.96 (0.81–1.14) 9 223 0.83 (0.68–1.01) 7 175 1.18 (0.91–1.53)*
A–C 14 359 0.98 (0.81–1.18) 7 184 0.83 (0.65–1.05) 7 175 1.18 (0.91–1.53)*
A–B 8 145 1.16 (0.85–1.57) 3 55 0.89 (0.62–1.27) 5 90 1.38 (0.92–2.06)*
A 7 116 1.10 (0.78–1.55) 3 55 0.89 (0.62–1.27) 4 61 1.40 (0.79–2.51)*
MM
A–E (all studies) 27 290 1.11 (0.97–1.26) 17 210 1.06 (0.92–1.22) 10 80 1.26 (0.92–1.71) 
A–D 15 166 1.13 (0.93–1.37) 8 111 1.06 (0.87–1.30) 7 55 1.27 (0.81–2.00)*
A–C 13 143 1.15 (0.91–1.44) 6 88 1.08 (0.86–1.34) 7 55 1.27 (0.81–2.00)*
A–B 8 75 1.40 (1.02–1.90) 3 35 1.20 (0.73–2.00)   5 40 1.58 (1.03–2.44) 
A 7 62 1.42 (0.97–2.08) 3 35 1.20 (0.73–2.00)   4 27 1.75 (0.94–3.26)
ALL
A–E (all studies) 18 47 1.41 (1.02–1.97) 11 30 1.27 (0.86–1.87) 7 17 1.92 (1.00–3.67)
A–D 18 47 1.41 (1.02–1.97) 11 30 1.27 (0.86–1.87) 7 17 1.92 (1.00–3.67)
A–C 12 29 1.36 (0.88–2.10) 6 15 1.04 (0.60–1.81) 6 14 2.10 (1.04–4.25)
A–B 8 16 1.59 (0.85–2.99) 3 5 0.98 (0.38–2.58) 5 11 2.28 (0.99–5.26)
A 6 12 1.52 (0.71–3.26) 2 3 0.88 (0.27–2.81)   4 9 2.30 (0.84–6.29)
CLL
A–E (all studies) 19 116 1.16 (0.81–1.65)* 12 74 0.91 (0.56–1.48)* 7 42 1.63 (1.09–2.44)
A–D 19 116 1.16 (0.81–1.65)* 12 74 0.91 (0.56–1.48)   7 42 1.63 (1.09–2.44)
A–C 14 98 1.20 (0.78–1.84)* 8 60 0.91 (0.47–1.75) 6 38 1.61 (1.00–2.59)
A–B 9 62 1.37 (0.80–2.35)* 5 43 1.13 (0.43–2.97)   4 19 1.84 (1.12–3.02)
A 7 50 1.36 (0.74–2.51) 4 41 1.40 (0.49–4.01) 3 9 1.33 (0.64–2.76)
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; HL, 
Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma. Data presented here correspond to Supplemental 
Material, Table 1 from Vlaanderen et al. (2011; http://dx.doi.org/10.1289/ehp.1002318). Sorahan et al. (2005) was categorized as 
follow-up starting before 1970; AML significance level A [relative risk > 1 (p < 0.1)]; exposure assessment quality D (qualitative 
indication that benzene exposure had occurred). No observed cases were reported for ALL by Sorahan et al. We therefore 
calculated continuity-corrected relative risks (observed and expected number of cases + 1) and estimated associated 95% confi-
dence intervals with mid-P exact.  Values that are different from those in the original analyses are in italic type.
aAML significance level categories: A, AML risk estimate > 1 (p < 0.1); B, AML risk estimate > 1 (p < 0.2); C, AML risk estimate > 1 
(p > 0.2); D, AML risk estimate reported; E, AML risk estimate not reported. bTwo of three studies reported null cases (continuity 
correction was applied in the meta-analysis). cOne of two studies reported null cases (continuity correction was applied in the 
meta-analysis). dNHL or lymphosarcoma/reticulosarcoma (preferred NHL if the study reported both). *p < 0.1 for between-study 
heterogeneity. 